Drug Class and Monitoring Parameters Flashcards

Enoxaparin sodium is classified as a blood modifier, primarily used to prevent and treat thromboembolic disorders.
Monitoring for enoxaparin sodium requires regular platelet count assessments to detect possible thrombocytopenia.
Cilostazol, marketed as Pletal, functions as a platelet inhibitor and is utilized in the treatment of intermittent claudication.

Enoxaparin sodium falls under pregnancy category B, indicating that it is considered safe for use during pregnancy based on available studies.
Cilostazol is categorized as pregnancy category C, suggesting that risk cannot be ruled out and should be considered when prescribing.
Apixaban (Eliquis) is also in pregnancy category B, meaning it is deemed to have a favorable safety profile during pregnancy.
Dabigatran Etexilate Mesylate (Pradaxa) is classified as pregnancy category C, advising caution due to potential risks.
Rivaroxaban (Xarelto) does not have a specific pregnancy category listed, indicating limited data regarding its use in pregnancy.
Warfarin sodium (Coumadin, Jantoven) is contraindicated during pregnancy as it poses significant risks to the fetus.
Clopidogrel bisulfate is categorized under pregnancy category B, implying it is generally safe for use in pregnant women.

Monitoring parameters for dabigatran Etexilate Mesylate include renal function tests (RFT) to assess kidney health.
Rivaroxaban requires both liver function tests (LFT) and renal function tests (RFT) for monitoring due to its metabolism and excretion pathways.
Warfarin sodium requires monitoring of International normalized ratio (INR) to ensure effective anticoagulation without excessive bleeding risk.

Four key hematological agents include:
- Dabigatran Etexilate Mesylate (Pradaxa)
- Cyanocobalamin (Nascobal), a vitamin B12 supplement
- Apixaban (Eliquis)
- Clopidogrel bisulfate (Plavix)